

HLS/SLS 22-

Regular Session, 2022

House/Senate Bill No. \_\_\_\_\_

By Representative/Senator \_\_\_\_\_

CONTROLLED SUBSTANCES: Updates language in regards to chemical structures of multiple substances in Schedule I, adds multiple substances to Schedule I, adds Daridorexant to Schedule IV, removes Fenfluramine from Schedule IV, and adds Ganaxolone to Schedule V.

## AN ACT

To amend and reenact R.S. 40:964, relative to structural language and the composition of various schedules of controlled substances.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:

§964. Composition of schedules

Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S. 40:962, consist of the following drugs or other substances, by whatever official name, common or usual name, chemical name, or brand name designated:

Schedule I

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, or salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

(1) – (99) ...

(100) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol)

\*

\*

\*

C. Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, for purposes of this Subsection only, the term "isomer" includes the optical, position, and geometric isomers:

(1) – (68) ...

(69) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (other name: FUB-144)

(70) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (other names: 5F-CUMYL-PINACA; SGT-25)

(71) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL))

(72) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (other name: 5F-EDMB-PINACA)

(73) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (other names: 5F-MDMB-PICA; 5F-MDMB-2201)

(74) alpha-pyrrolidinopentiophenone ( $\alpha$ -PVP)

(75) N-Ethylhexedrone (Other names:  $\alpha$ -ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one)

(76) 4'-Chloro-alpha-pyrrolidinovalerophenone (Other names: 4-chloro- $\alpha$ -PVP; 4'-chloro- $\alpha$ -pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one)

(77) alpha-Pyrrolidinoheptaphenone (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one)

(78) 4'-Methyl-alpha-pyrrolidinohexiophenone (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one)

(79) 4-Methyl-alpha-ethylaminopentiophenone (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one)

(80) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE)

\*

\*

\*

#### E. Stimulants

Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Federal Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible within the specific chemical designation:

(1) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the following ways:

- (i) By substitution ~~in~~ on the phenyl ring to any extent with an alkyl, hydroxyl alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted ~~in~~ on the phenyl ring by one or more other univalent substituents.
- (ii) By substitution at the 3-position with an alkyl substituent.
- (iii) By substitution at the 2-amino nitrogen atom with alkyl, cycloalkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

(2) – (7) ...

(8) Naphthylpyrovalerone whether or not further substituted ~~in~~ on the naphthyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted ~~in~~ on the naphthyl ring by one or more other univalent substituents or whether or not further substituted ~~in~~ on the carbon chain at the 3, 4, or 5 position with an alkyl substituent.

(9) – (13) ...

(14) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid)

(15) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate)

(16) Methiopropamine (N-methyl-1-(thiophen-2-yl)propane-2-amine)

#### F. Synthetic Cannabinoids

Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following individual compounds or chemical groups, or any of those individual compounds or groups which contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible within the specific compounds or chemical groups:

- (1) Adamantoylindoles: any compound containing a 3-(1-adamantoyl)indole structure, whether or not further substituted ~~in~~ on the indole ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any extent.
- (2) Adamantylamidindoles: Any compound containing a N-(adamantyl)-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any extent.
- (3) Benzoylindoles: any compound containing a 3-(benzoyl)indole structure, whether or not substituted ~~in~~ on the indole ring to any extent or whether or not substituted on the phenyl ring to any extent.
- (4) Benzyndolecarboxamides: Any compound containing a N-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole ring or whether or not substituted on the phenyl ring to any extent.

- (5) Butaldehydeamidoindoles: Any compound containing a N-(1-oxobutan-2-yl)-1H-indole-3-carboxamide structure, with or without substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, ~~alkylarylhalide~~ arylalkylhalide, ~~cycloalkylmethyl~~ cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further substituted on the butaldehyde group to any extent.
- (6) Cumylindolecarboxamides: Any compound containing a N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, ~~alkylarylhalide~~ arylalkylhalide, ~~cycloalkylmethyl~~ cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further substituted on the phenyl group to any extent.
- (7) Cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl)phenol structure, whether or not substituted ~~in~~ on the cyclohexyl ring to any extent or whether or not substituted on the phenyl ring to any extent.
- (8) Cyclopropanoylindoles: any compound containing a 3-(cyclopropanoyl)indole structure, whether or not substituted ~~in~~ on the

- 144 indole ring to any extent or whether or not substituted on the  
145 cyclopropyl ring to any extent.
- 146 (9) – (11) ...
- 147 (12) Hexahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic  
148 ring system to any extent except where contained in cannabis or  
149 cannabis resin.
- 150 (13) – (16) ...
- 151 (17) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole  
152 structure, whether or not substituted ~~in~~ on the indole ring to any extent  
153 or whether or not substituted on the naphthyl ring to any extent.
- 154 (18) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole  
155 structure, whether or not substituted ~~in~~ on the pyrrole ring to any extent  
156 or whether or not substituted on the naphthyl ring to any extent.
- 157 (19) Naphthylamidindoles: any compound containing a N-(naphthyl)-1H-  
158 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on  
159 the indole ring to any extent or whether or not substituted ~~in~~ on the  
160 naphthyl ring to any extent.
- 161 (20) Naphthylindolecarboxylates: Any compound containing a naphthyl-1H-  
162 indole-3-carboxylate structure, whether or not further substituted ~~in~~ on  
163 the indole ring or whether or not substituted on the naphthyl ring to any  
164 extent.
- 165 (21) Naphthylmethylindenes: any compound containing a 1-(1-  
166 naphthylmethyl)indene structure, whether or not substituted ~~in~~ on the

- 167 indene ring to any extent or whether or not substituted on the naphthyl  
168 ring to any extent.
- 169 (22) Naphthylmethylindeles: any compound containing a 1-H-indol-3-yl-(1-  
170 naphthyl)methane structure, whether or not substituted ~~in~~ on the indole  
171 ring to any extent or whether or not substituted on the naphthyl ring to  
172 any extent.
- 173 (23) ...
- 174 (24) Phenylacetylindeles: any compound containing a 3-phenylacetylindele  
175 structure, whether or not substituted ~~in~~ on the indole ring to any extent  
176 or whether or not substituted on the phenyl ring to any extent.
- 177 (25) Phenylindolecarboxamides: Any compound containing a N-phenyl-1H-  
178 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on  
179 the indole ring or whether or not substituted on the phenyl ring to any  
180 extent.
- 181 (26) Phenylpropionaldehydeamidoindoles: Any compound containing a N-(1-  
182 oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or  
183 without substitution ~~in~~ on the indole ring by an alkyl, haloalkyl,  
184 cyanoalkyl, alkoxy, aryl, aryl halide, ~~alkylarylhalide~~ arylalkylhalide,  
185 ~~cycloalkylmethyl~~ cycloalkylmethyl, cycloalkylethyl, alkenyl,  
186 haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,  
187 alkylmorpholinomethyl, alkylpiperidinylmethyl or a  
188 tetrahydropyranylmethyl group, whether or not further substituted on the  
189 phenylpropionaldehyde group to any extent.



- (27) Quinolinyndolecarboxamides: Any compound containing a N-quinolinyndole-3-carboxamide or N-isoquinolinyndole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole, quinoline or the isoquinoline ring to any extent.
- (28) Quinolinyndolecarboxylates: any compound containing a quinolin-8-yl-1H-indole-3-carboxylate or isoquinolin-8-yl-1H-indole-3-carboxylate structure, whether or not further substituted ~~in~~ on the indole, quinoline, or isoquinoline ring to any extent.
- (29) Tetrahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic ring system to any extent except where contained in cannabis or cannabis resin.

\* \* \*

Schedule IV

\* \* \*

B. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) – (57) ...

(58) Daridorexant

~~C. Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of isomers,~~

~~whenever the existence of such salts, isomers, and salts of isomers~~  
~~including Fenfluramine is possible.~~

~~D.~~ C. Stimulants. Unless specifically excepted or unless listed in another  
 schedule, any material, compound, mixture, or preparation which contains  
 any quantity of the following substances, including its salts, isomers, and  
 salts of isomers:

(1) – (15) ...

~~E.~~ D. Other substances. Unless specifically excepted or unless listed in another  
 schedule, any material, compound, mixture, or preparation which contains  
 any quantity of the following substances, including its salts:

(1) – (3) ...

\* \* \*

~~F.~~ E. *Miscellaneous. Unless specifically excepted or contained within a  
 pharmaceutical product approved by the United States Food and Drug  
 Administration, or unless listed in another schedule, any material,  
 compound, mixture, or preparation which contains any quantity of the  
 following substances including its salts, isomers, or salts of isomers,  
 whenever the existence of such salts, isomers, or salts of isomers is  
 possible within the specific chemical designation:*

*(1) Mitragynine*

*(2) 7-Hydroxy-mitragynine*

\* \* \*

Schedule V

\* \* \*

238 D. Depressants. Unless specifically exempted or excluded or unless listed in  
239 another schedule, any material, compound, mixture, or preparation which  
240 contains any quantity of the following substances having a depressant  
241 effect on the central nervous system, including its salts:

242 (1) – (5) ...

243 (6) Pregabalin

244 (7) Ganaxolone (3 $\alpha$ -hydroxy-3 $\beta$ -methyl-5 $\alpha$ -pregnan-20-one)

245 \* \* \*

246 Section 2. The Louisiana State Law Institute is hereby authorized and directed to  
247 alphabetize the new entries.

248 [END]